Passage Bio Inc
NASDAQ:PASG
Passage Bio Inc
NASDAQ:PASG
Price:
3.4
USD
2.41%
Market Closed
Market Cap:
$10.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Passage Bio Inc
NASDAQ:PASG
|
US |
|
S
|
Standard Industries Ltd
NSE:SIL
|
IN |
|
Olam Group Ltd
SGX:VC2
|
SG |
|
Tompkins Financial Corp
F:8J0
|
US |
|
Mishra Dhatu Nigam Ltd
NSE:MIDHANI
|
IN |
|
V
|
Vinci SA
F:SQUA
|
FR |
|
Metal Powder Works Ltd
F:3OV
|
AU |
|
H
|
Helmerich and Payne Inc
XMUN:HPC
|
US |
|
J
|
JCDecaux SE
DUS:DCS
|
FR |
|
O
|
Orron Energy AB
DUS:LYV
|
SE |
|
Astellas Pharma Inc
F:YPHA
|
JP |
|
First Capital SpA
MIL:FIC
|
IT |
|
N
|
Nokia Oyj
PSE:NOKIA
|
FI |
|
P
|
Public Storage
F:PUP
|
US |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
La Francaise de l Energie SA
F:LFX
|
FR |
Intrinsic Value
Not Available for PASG
There is not enough data to reliably calculate the intrinsic value for Passage Bio Inc.
Do our valuations actually work? See backtest results .
Alternatives to PASG
Fundamental Analysis
What Passage Bio Does
Passage Bio is a biotechnology company that develops gene therapies for rare genetic diseases, especially disorders that affect the brain and nervous system. Its main work is to design treatments that replace or repair faulty genes, with a focus on diseases that have few or no good treatment options.
- Headquarters
- United States of America US
- Employees
- 24
- IPO date
- Feb 28, 2020
Financials
Efficiency
Earnings Waterfall
Passage Bio Inc
Passage Bio Inc
